🇺🇸 FDA
Patent

US 10774066

Prodrugs of NRF2 activating compounds and uses thereof

granted A61PA61P17/06A61P37/02

Quick answer

US patent 10774066 (Prodrugs of NRF2 activating compounds and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P17/06, A61P37/02